Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 30, 2023

Primary Completion Date

January 16, 2025

Study Completion Date

January 16, 2025

Conditions
OverweightObesity
Interventions
DRUG

Semaglutide

Participants will receive semaglutide tablets orally once daily for 44 weeks.

DRUG

Semaglutide Placebo

Participants will receive placebo matched to semaglutide.

Trial Locations (15)

100044

Peking University People's Hospital-Endocrinology, Beijing

100050

Beijing Friendship Hospital, Capital Medical University-Endocrinology, Beijing

200040

Huashan Hospital Fudan University-Endocrinology, Shanghai

201200

Shanghai Pudong New Area People's Hospital-Endocrinology, Shanghai

210011

The Second Affiliated Hospital of Nanjing Medical University, Nanjing

212001

The Affiliated Hospital of Jiangsu University, Zhenjiang

213003

Changzhou No.2 People's Hospital, Changzhou

250013

Jinan Central Hospital, Ji'nan

300052

General Hospital of Tianjin Medical University-Endocrinology, Tianjin

404000

Chongqing University Three Gorges Hospital, Chongqing

415003

The First People's Hospital of Changde City-Endocrinology, Changde

442008

Taihe Hospital, Shiyan

450062

The First Affiliated Hospital of Henan University of science and Technology, Luoyang

475000

Huaihe Hospital of Henan University-Endocrinology, Kaifeng

516001

Huizhou Central People's Hospital-Endocrinology, Huizhou

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT05890976 - Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3) | Biotech Hunter | Biotech Hunter